Ranolazine: A new option in the management of chronic stable angina

Pharmacotherapy

Volumn 27, Issue 12 I, 2007, Pages 1659-1676

  Dobesh, Paul P ^a,c   Trujillo, Toby C ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antianginal agent; Chronic stable angina; Ranolazine

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CVT 2512; CVT 2514; CVT 2738; CVT 4786; DIGOXIN; DILTIAZEM; DOFETILIDE; DRUG METABOLITE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; KETOCONAZOLE; NITRIC ACID DERIVATIVE; PAROXETINE; PENTOBARBITAL; PLACEBO; RANOLAZINE; SIMVASTATIN; SOTALOL; UNCLASSIFIED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ADD ON THERAPY; ASTHENIA; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE TOLERANCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART DEPOLARIZATION; HEART PALPITATION; HEART RATE; HUMAN; NAUSEA; NONHUMAN; QT INTERVAL; QT PROLONGATION; REVASCULARIZATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STABLE ANGINA PECTORIS; SUSTAINED DRUG RELEASE; SYNCOPE; TORSADE DES POINTES;

ACETANILIDES; ANGINA PECTORIS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 36849034850     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12.1659     Document Type: Review

References (77)

1. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1999 guidelines for the management of patients with chronic stable angina). Available from http://www.acc.org/ qualityandscience/clinical/guidelines/stable/stable_clean.pdf. Accessed September 19, 2006.
2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006;113:e85-151. Available from http://circ.ahajournals.org/cgi/reprint/ CIRCULATIONAHA.105.171600v1. Accessed September 19, 2006.
3. Holubkov R, Laskey WK, Haviland A, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI dynamic registry. Am Heart J 2002;144:826-33.
4. Serruys PW, Unger F, Sousa JE, et al, for the Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
5. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. JAMA 1997;277:715-21.
6. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker of diltiazem. J Cardiovasc Pharmacol 1992;20:131-8.
7. Thadani U, Ezekowitz M, Fenney L, Chiang YK, for the Ranolazine Study Group. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 1994;90:726-34.
8. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional anti-anginal agents. Am J Cardiol 1999;84:46-50.
9. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311-26.
10. Jerling M, Huan B-H, Leung K, Chu N, Abdallah H, Hussein Z. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005;45:422-33.
11. Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005;78:288-97.
12. Gordon M. Medical review of safety (ranolazine). Rockville, MD: U.S. Food and Drug Administration, February 2003. Available from http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 4012B2_02_Division%20Dir%20%20Memo.htm. Accessed August 22, 2006.
13. Chaitman BR, Skettino SL, Parker JO, et al, for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82.
14. Chaitman BR, Pepine CJ, Parker JO, et al, for the CARISA Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-16.
15. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: a review of evidence from clinical trials. J Cardiovasc Pharmacol Ther 2004;9(suppl 1):S47-64.
16. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005;45:802-9.
17. CV Therapeutics, Inc. Ranexa (ranolazine) package insert. Palo Alto, CA; 2006.
18. Stone PH, Gratsiansky NA, Blokhin A, Huang I-Z, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol 2006;48:566-75.
19. 2-adrenoceptor antagonist in the rat cardiovascular system. Nauyn Schmiedebergs Arch Pharmacol 2001;363:464-71.
20. Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 1996;118:249-54.
21. Chaitman BR. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor. Curr Probl Cardiol 2002;27:527-55.
22. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of heart disease: the clinicians' perspective. Heart Fail Rev 2002;7:187-203.
23. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J Suppl 2004;6:13-7.
24. Saint DA, Ju Y-K, Gage PW. A persistent sodium current in rat ventricular myocytes. J Physiol 1992;453:219-31.
25. Kiyosue T, Arita M. Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ Res 1989;64:389-97.
26. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992;71:1231-41.
27. Wasserstrom JA, Salata JJ. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. Am J Physiol 1988;254:H1157-66.
28. Maltsev VA, Sabbah HN, Higgins RSD, Silverman N, Lesch M, Undrovinas AI. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998;98:2545-52.
29. Pike MM, Kitakaze M, Marban E. Na-NMR measurement of intracellular sodium in intact perfused ferret hearts during ischemia and reperfusion. Am J Physiol 1990;259:H1767-73.
30. Kusuoka H, Marban E. Cellular mechanisms of myocardial stunning. Annu Rev Physiol 1992;54:243-56.
31. Kusuoka H, Hurtado MCC, Marban E. Role of sodium/calcium exchange in the mechanism of stunning: protective effect of reperfusion with high sodium solution. J Am Coll Cardiol 1993;21:240-8.
32. Imahashi K, Kusuoka H, Hashimoto K, Yoshioka J, Yamaguchi H, Nishimura T. Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res 1999;84:1401-6.
33. Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res 1991;68:1250-8.
34. Steenbergen C, Murphy E, Watts JA, London RE. Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemia injury in perfused rat heart. Circ Res 1990;66:135-46.
35. Barry WH, Peeters GA, Rasmussen AF Jr, Cunningham MJ. Role of changes in [Ca2+]i in energy deprivation contracture. Circ Res 1987;61:726-34.
36. 2+], Hi elevation, and ATP depletion. Am J Physiol 1990;258:H9-16.
37. Steenbergen C, Murphy E, Levy L, London RE. Elevation in cytosolic free calcium concentration early in myocardial ischemia in perfused rat heart. Circ Res 1987;60:700-7.
38. Bers DM, Barry WH, Despa S. Intracellular Na+ regulation in cardiac myocytes. Cardiovasc Res 2003;57:897-912.
39. Murphy E, Cross H, Steenbergen C. Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res 1999;84:1469-70.
40. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Therapeut 2004;9(suppl 1):S65-83.
41. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10.
42. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004;310:599-605.
43. Meyer M, Keweloh B, Guth K, et al. Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new model for the measurement of oxygen consumption in muscle strip preparations. J Mol Cell Cardiol 1998;30:1459-70.
44. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994;8:741-7.
45. Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS-43285): a preliminary study of a new antianginal agent with selective effect on ischaemic myocardium. Br J Clin Pharmacol 1990;38:111-14.
46. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1C in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-8.
47. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the ranolazine open label experience (ROLE). J Am Coll Cardiol 2007;49:1027-34.
48. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987;106:793-800.
49. Alexander KP, Shaw LJ, Deling ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998;32:1657-64.
50. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERL1N-TIMI 36 trial. JAMA 2007;297:1775-83.
51. Cobbe S. Electrophysiological perspectives: what has ranolazine taught us? Eur Heart J 2004;6(suppl):I9-11.
52. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006;113:2462-72.
53. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.
54. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003;24:619-25.
55. Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle: the M cell. Circ Res 1991;68:1729-41.
56. Antzelevitch C, Sicouri S, Litovsky SH, et al. Heterogeneity within the ventricular wall: electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ Res 1991;69:1427-49.
57. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiologic properties of epicardium, midmyocardium and endocardium: in vitro and in vivo correlations. Circulation 1996;94:1981-8.
58. Singh BN, Wadhani N. Antiarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Therapeut 2004;9(suppl 1):S85-97.
59. Shimizu W, McMahon B, Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndromes. J Cardiovasc Electrophysiol 1999;10:156-64.
60. Weissenburger J, Nesterenko W, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 2000;11:290-304.
61. Hohnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Inter Med 1994;121:529-35.
62. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997;350:1417-24.
63. Zygmunt AC, Eddlestone GT, Thomas GP, et al. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol 2001;281:H689-97.
64. McGraw BF, Hemberger JA, Smith AL, Schroeder JS. Variability of exercise performance during long-term placebo treatment. Clin Pharmacol Ther 1981;30:321-7.
65. Walters DD, McCans JL, Crean PA. Serial exercise testing in patients with effort angina: variable tolerance, fixed threshold. J Am Coll Cardiol 1985;6:1011-15.
66. Thadani U, Zellner SR, Glasser S, et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine: a new second-generation calcium channel blocker in angina pectoris. Circulation 1991;84:2398-408.
67. Thadani U, Chrysant S, Gorwit J, et al. Duration of effects of isardipine during twice daily therapy in angina pectoris. Cardiovasc Drugs Ther 1994;8:199-210.
68. Thadani U, Bittar N. Effects of 8:00 am and 2:00 pm doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris. Am J Cardiol 1992;70:286-92.
69. Thadani U, Glasser S, Bittar N, et al, for the Diltiazem CD Study Group. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol 1994;74:9-17.
70. Weiss R, Ferry D, Pickering E, et al, for the Carvedilol-Angina-Study Group. Effectiveness of three different doses of Carvedilol for exertional angina. Am J Cardiol 1998;82:927-31.
71. Stone PH, Gibson RS, Glasser SP, et al, for the ASIS Study Group. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 1990;82:1962-72.
72. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol, and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 1995;25:619-25.
73. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999;83:507-14.
74. Parker JO, Amies MH, Hawkinson RW, et al, for the Minitran Efficacy Study Group. Intermittent transdermal nitroglycerin therapy in angina pectoris: clinically effective without tolerance or rebound. Circulation 1995;91:1368-74.
75. Parisi AF, Folland ED, Hartigan P, for the Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-16.
76. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-70.
77. Cairns JA. Ranolazine: augmenting the antianginal armamentarium. J Am Coll Cardiol 2006;48:576-8.